PeptideSearch

Dihexa

Animal studies only

Get notified when the evidence changes.

Almost all the research is in animals. We do not know if the same thing happens in people.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-04-15

Also called N-hexanoic-Tyr-Ile-(6) aminohexanoic amide / PNB-0408

Studied in rats for building new connections between brain cells. No human data.

Official status: 503A Category 2 – significant safety risk · Checked 2026-04-15

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Still restricted. The FDA has said it plans to review this one by February 2027.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 5

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for Dihexa. Unsubscribe in one click.